Wintest
6721
Showcase
3909
Beauty Kadan Holdings
3041
Cybozu
4776
KODAMA CHEMICAL INDUSTRY
4222
(FY)Sep 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 51.49%107.78B | 76.01%26.3B | 40.06%24.39B | 20.20%71.15B | 97.34%23.11B | -4.10%15.68B | -3.35%14.94B | 11.12%17.42B | 296.63%59.19B | 519.94%11.71B |
Cost of revenue | 54.85%69.44B | 86.92%16.63B | 65.85%13.58B | 10.54%44.84B | 126.47%18.1B | -12.08%9.66B | -19.05%8.9B | -22.73%8.19B | 1,149.66%40.56B | 1,107.57%7.99B |
Gross profit | 45.76%38.35B | 59.97%9.67B | 17.19%10.81B | 41.22%26.31B | 34.84%5.02B | 12.24%6.02B | 35.26%6.05B | 81.76%9.23B | 59.53%18.63B | 203.31%3.72B |
Operating expense | 20.79%9.71B | 27.24%2.3B | 16.71%2.49B | 16.82%8.04B | 18.40%2.14B | 14.82%1.95B | 6.41%1.81B | 27.75%2.14B | 6.83%6.88B | 13.57%1.81B |
Operating profit | 56.76%28.63B | 73.96%7.37B | 17.33%8.32B | 55.52%18.27B | 50.42%2.87B | 11.04%4.07B | 52.98%4.24B | 108.28%7.09B | 124.40%11.75B | 620.05%1.91B |
Net non-operating interest income (expenses) | 121.40%61M | 132.89%49M | 705.26%115M | -58.33%-285M | -25.32%-99M | 10.00%-18M | -325.71%-149M | 58.70%-19M | 47.98%-180M | 36.28%-79M |
Non-operating interest income | 0.26%781M | 27.91%165M | 37.44%268M | 232.91%779M | 449.06%291M | 82.22%164M | 214.63%129M | 290.00%195M | -41.65%234M | 136.83%53M |
Non-operating interest expense | -32.33%720M | -58.27%116M | -28.50%153M | 157.63%1.06B | 195.45%390M | 66.97%182M | 265.79%278M | 122.92%214M | -44.71%413M | -9.82%132M |
Total other finance cost | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1M | --0 |
Net investment income | 45.04%-865M | 24.41%-192M | -0.61%-329M | -1,200.70%-1.57B | -349.70%-751M | -229.41%-242M | -361.86%-254M | -1,357.69%-327M | 121.28%143M | -213.64%-167M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 101.96%309M | 300.00%104M | 233.33%130M | -78.30%153M | -71.78%46M | -78.46%42M | -84.34%26M | -78.45%39M | -38.21%705M | -33.71%163M |
Income from associates and other participating interests | 63.06%362M | 740.00%42M | 127.45%232M | 484.21%222M | 1,900.00%80M | -33.96%35M | 110.87%5M | 277.78%102M | -74.15%38M | 112.16%4M |
Special income (charges) | 370.70%582M | 0 | 262.57%569M | -141.57%-215M | -237.50%-135M | 687.23%276M | -6M | -17,400.00%-350M | 88.04%-89M | 81.00%-40M |
Less:Impairment of capital assets | -90.63%12M | --0 | --12M | --128M | ---- | ---- | --0 | --0 | --0 | ---- |
Less:Other special charges | -120.37%-595M | --0 | -29,150.00%-581M | -1,900.00%-270M | --0 | ---281M | --9M | 0.00%2M | -93.59%15M | 234.19%13M |
Less:Write off | -99.72%1M | --0 | --0 | 382.43%357M | -74.07%7M | -89.36%5M | ---3M | --348M | -76.73%74M | -4.49%27M |
Other non-operating income (expenses) | -71.90%360M | -94.18%17M | -15.03%130M | 1,763.64%1.28B | 2,010.71%535M | 204.04%301M | 370.37%292M | 482.50%153M | 64.68%-77M | -455.33%-28M |
Income before tax | 64.88%29.44B | 78.02%7.39B | 37.12%9.17B | 45.36%17.86B | 45.01%2.56B | 8.15%4.46B | 45.92%4.15B | 88.31%6.69B | 170.51%12.28B | 626.57%1.76B |
Income tax | 67.46%8.97B | 94.33%2.26B | 29.20%2.74B | 39.33%5.36B | 35.43%688M | 2.98%1.38B | 18.55%1.16B | 109.58%2.12B | 142.07%3.84B | 345.83%508M |
Net income | 63.79%20.47B | 71.73%5.13B | 40.78%6.43B | 48.11%12.5B | 48.92%1.87B | 10.63%3.08B | 60.28%2.99B | 79.90%4.56B | 185.87%8.44B | 378.92%1.26B |
Net income continuous operations | 63.78%20.47B | 71.68%5.13B | 40.80%6.43B | 48.10%12.5B | 48.89%1.87B | 10.64%3.08B | 60.33%2.99B | 79.83%4.56B | 185.81%8.44B | 379.77%1.26B |
Noncontrolling interests | -54.55%15M | -283.33%-11M | 1,300.00%42M | 191.67%33M | 42.86%10M | 151.85%14M | 118.18%6M | -82.35%3M | -820.00%-36M | -70.77%7M |
Net income attributable to the company | 64.10%20.46B | 72.39%5.14B | 39.96%6.38B | 47.09%12.47B | 49.16%1.86B | 9.04%3.07B | 57.06%2.98B | 81.02%4.56B | 187.68%8.48B | 362.59%1.25B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 64.10%20.46B | 72.39%5.14B | 39.96%6.38B | 47.09%12.47B | 49.16%1.86B | 9.04%3.07B | 57.06%2.98B | 81.02%4.56B | 187.68%8.48B | 362.59%1.25B |
Gross dividend payment | ||||||||||
Basic earnings per share | 64.47%240.07 | 72.41%60.17 | 39.96%74.74 | 47.09%145.97 | 49.01%21.77 | 9.09%35.9 | 57.07%34.9 | 81.02%53.4 | 187.57%99.24 | 362.77%14.61 |
Diluted earnings per share | 64.47%240.07 | 72.41%60.17 | 39.96%74.74 | 47.09%145.97 | 49.10%21.77 | 9.05%35.8887 | 57.07%34.9 | 81.02%53.4 | 187.57%99.24 | 362.60%14.6011 |
Dividend per share | 64.79%120.3 | 38.75 | 0 | 46.00%73 | 46.00%73 | 0 | 0 | 0 | 203.03%50 | 203.03%50 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |